Edward Forchion, the cannabis advocate known as “NJ Weedman,” is running a write-in campaign for New Jersey governor following a successful challenge of his nominating petitions by the Democratic State Committee, NJ.com reports.
Articles
Atai IPO Day An Underwhelming Event
The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
Medical marijuana patients, adult-use customers alike using cannabis for wellness
Recreational marijuana makes the most headlines, but a large number of cannabis consumers buy and use the plant for medical and wellness reasons.
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Rainbo’s Tonya Papanikolov Believes in the Magic of Mushrooms
Tonya Papanikolov could talk about mushrooms for hours.
It Begins: Bill Introduced Into Congress To Decriminalize All Drugs
A bill to decriminalize drug possession has been introduced into Congress. If passed, jurisdiction for drug classifying would move from the Justice Department to the Department of Health and Human Services.
Creso Pharma and Red Light Holland Merge to Introduce The HighBrid Lab (TM), a Leading Global Psychedelics x Cannabis Company, Specializing in Recreational Products, Applied Science, Technology and Innovation
Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences has applied to uplist to the NASDAQ.
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Rhode Island Marijuana Legalization Bill Approved In Senate Committee
A Rhode Island Senate committee on Monday approved a marijuana legalization bill that’s being championed by leadership in the chamber.
‘I’m a lighter me’: Can Mike Tyson and psychedelics help boxers with brain trauma?
The former heavyweight champion says psychedelics would have helped him with his mental health during his career. Some scientists and companies agree
Atai To Upsize IPO Financing To $246 Million, The Industry Leader Just Got Bigger
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.